T-cell Discovery for Lupus

World-first discovery may enable an effective long-term lupus treatment 06 February 2024 Two years away from clinical trials, the method targets the T-cell in the immune system – offering patients the possibility of a treatment beyond medication and its side effects. Australian researchers have worked out how to fix a defect that causes lupus, and…

Details

Lupus Sub Group of Type 2

Research Reveals Unique Sub-Groups of Type 2 Lupus (Extract from Lupus Foundation of America) A new study provides insights into the nature of symptoms experienced by people with lupus. While Type 1 and Type 2 lupus models (described below) have previously been identified, the latest research expands upon and refines these definitions, revealing two new…

Details

mRNA COVID-19 Vaccine

Study Finds mRNA COVID-19 Vaccine and One Booster Dose May Not Fully Protect against Breakthrough Case of Omicron Variant in People with Autoimmune Disease In people with autoimmune rheumatic diseases (ARDs), such as lupus, the mRNA COVID-19 vaccine and booster dose may not provide broad protection from developing a breakthrough infection (an infection with a…

Details

Alpha Project 2

Global Advisory Committee Identifies Solutions for Addressing Top Lupus Barriers The Addressing Lupus Pillars for Health Advancement (ALPHA) project is a unique global consensus initiative that seeks to identify and prioritize the fundamental barriers or knowledge gaps that will allow providers, researchers and scientists to improve diagnosis, treatment and systems of care for people with…

Details

US FDA approves Lupkynis (voclosporin)

More great news for people with lupus! The U.S. Food and Drug Administration (FDA) has approved Lupkynis™ (voclosporin) to treat lupus nephritis (lupus-related kidney disease) in adults when used in combination with a background immunosuppressive therapy regimen. Lupkynis is the second new therapy authorized to treat this potentially life-threatening complication of lupus. Developed by Aurinia…

Details